Nitin Patel

1.1k total citations
19 papers, 56 citations indexed

About

Nitin Patel is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Nitin Patel has authored 19 papers receiving a total of 56 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 13 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Nitin Patel's work include Multiple Myeloma Research and Treatments (17 papers), Protein Degradation and Inhibitors (12 papers) and CAR-T cell therapy research (10 papers). Nitin Patel is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Protein Degradation and Inhibitors (12 papers) and CAR-T cell therapy research (10 papers). Nitin Patel collaborates with scholars based in United States, Spain and Germany. Nitin Patel's co-authors include Nikoletta Lendvai, Jordan M. Schecter, Hermann Einsele, Carolina Lonardi, Simon J. Harrison, Jesús F. San Miguel, Francesca Ghilotti, Katherine Li, Rakesh Popat and Surbhi Sidana and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Nitin Patel

17 papers receiving 54 citations

Peers

Countries citing papers authored by Nitin Patel

Since Specialization

Citations

This map shows the geographic impact of Nitin Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nitin Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nitin Patel more than expected).

Fields of papers citing papers by Nitin Patel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nitin Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nitin Patel. The network helps show where Nitin Patel may publish in the future.

Co-authorship network of co-authors of Nitin Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Nitin Patel. A scholar is included among the top collaborators of Nitin Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nitin Patel. Nitin Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	POSTER: MM-1070 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 Survival Subgroup Analyses 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Surbhi Sidana, Joaquín Martínez‐López, (unknown), Albert Oriol, Andrew Spencer, Binod Dhakal, Yaël C. Cohen, Cyrille Touzeau, Dominik Dytfeld, Hermann Einsele, Jesús F. San Miguel, Salomon Manier, Diana Chen, Katherine Li, (unknown), Carolina Lonardi, Arnab Ghosh, Nitin Patel, Erika Florendo, Simon J. Harrison	0
2	Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting 2025 ·Advances in Therapy ·Rafaël Fonseca, Joris Diels, Francesca Ghilotti, J. Mendes, (unknown), (unknown), Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, (unknown), Winfried Alsdorf, Niels W.C.J. van de Donk, (unknown)	2
3	Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Binod Dhakal, Jinghua He, Jordan M. Schecter, William Deraedt, Ana Slaughter, Carolina Lonardi, Sandhya Nair, Jianming He, (unknown), (unknown), Nitin Patel, Mythili Koneru, Hermann Einsele	1
4	Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). 2025 ·Journal of Clinical Oncology ·Peter M. Voorhees, Tom Martin, Yi Lin, Adam D. Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesús G. Berdeja, Binod Dhakal, Andrzej Jakubowiak, Samir Parekh, Huijun Li, Rocío Montes de, (unknown), Nikoletta Lendvai, Deepu Madduri, Mythili Koneru, Nitin Patel, Sundar Jagannath	1
5	Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. 2025 ·Journal of Clinical Oncology ·Surbhi Sidana, Joaquín Martínez‐López, Abdullah Khan, Albert Oriol, Andrew Spencer, Binod Dhakal, Yaël C. Cohen, Cyrille Touzeau, Dominik Dytfeld, Hermann Einsele, Jesús F. San Miguel, Salomon Manier, Ying Chen, Katherine Li, (unknown), Carolina Lonardi, Arnab Ghosh, Nitin Patel, Erika Florendo, Simon J. Harrison	1
6	Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. 2024 ·Journal of Clinical Oncology ·Luciano J. Costa, Katja Weisel, (unknown), Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquín Martínez‐López, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, (unknown), Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, (unknown), María‐Victoria Mateos	2
7	MM-549 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Luciano J. Costa, Katja Weisel, (unknown), Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquín Martínez‐López, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, (unknown), Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, (unknown), (unknown)	0
8	Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting 2024 ·Journal of Comparative Effectiveness Research ·Winfried Alsdorf, Joris Diels, Francesca Ghilotti, J. Mendes, (unknown), (unknown), Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, (unknown), (unknown)	3
9	Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma 2024 ·Blood ·Michel Delforge, (unknown), María‐Victoria Mateos, Kristina Carlson, Keqin Qi, J. Mendes, (unknown), Jordan M. Schecter, William Deraedt, Carolina Lonardi, Ana Slaughter, Diana Chen, (unknown), (unknown), Nitin Patel, Erika Florendo, Hermann Einsele, Binod Dhakal, Wilfried Roeloffzen	3
10	Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials 2024 ·European Journal of Cancer ·Kwee Yong, Hermann Einsele, Jordan M. Schecter, Tito Roccia, William Deraedt, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, (unknown), Keqin Qi, Anil Londhe, Richard G. Carson, (unknown), (unknown), Satish Valluri, J. Mendes, Lida Pacaud, Nitin Patel, Erika Florendo, Binod Dhakal	2
11	Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma 2024 ·Future Oncology ·Jesús F. San Miguel, Binod Dhakal, Nitin Patel, Jordan M. Schecter, Nikoletta Lendvai, Hermann Einsele	1
12	Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma 2024 ·Expert Opinion on Biological Therapy ·Sundar Jagannath, Carolyn C. Jackson, Jordan M. Schecter, Nikoletta Lendvai, (unknown), (unknown), Nitin Patel, Thomas G. Martin	4
13	Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Luciano J. Costa, Katja Weisel, (unknown), Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquín Martínez‐López, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, (unknown), Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, (unknown), María‐Victoria Mateos	1
14	Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison 2024 ·Current Medical Research and Opinion ·Noffar Bar, Joris Diels, Suzy Van Sanden, (unknown), (unknown), Heather Burnett, (unknown), Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, (unknown), Simon J. Harrison, (unknown)	1
15	Efficacy of Carvykti in CARTITUDE-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting 2023 ·Blood ·Winfried Alsdorf, Joris Diels, Francesca Ghilotti, (unknown), (unknown), (unknown), Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, (unknown), Carlos Fernández de Larrea, (unknown)	3
16	First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. 2023 ·Journal of Clinical Oncology ·Binod Dhakal, Kwee Yong, Simon J. Harrison, María‐Victoria Mateos, Philippe Moreau, Niels W.C.J. van de Donk, Surbhi Sidana, Rakesh Popat, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan M. Schecter, Katherine Li, Enrique Zudaire, Ying Chen, (unknown), Lida Bubuteishvili‐Pacaud, Nitin Patel, Jesús F. San Miguel, Hermann Einsele	20
17	Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison 2023 ·Blood ·Noffar Bar, Joris Diels, Suzy Van Sanden, J. Mendes, (unknown), (unknown), Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, (unknown), Simon J. Harrison, (unknown)	5
18	ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296]. 2022 ·Journal of Clinical Oncology* ·Dejka M. Araujo, Brian H. Ladle, (unknown), Benjamin Powers, (unknown), Ionel Mitrica, Wenlei Liu, Nitin Patel, Sandra P. D’Angelo	3
19	P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY 2022 ·HemaSphere ·Attaya Suvannasankha, Nizar J. Bahlis, (unknown), Katja Weisel, Christian Koenecke, Albert Oriol, Peter M. Voorhees, (unknown), Natalie S. Callander, María‐Victoria Mateos, Nishitha Reddy, (unknown), Nitin Patel, (unknown), Roxanne C. Jewell, Xiaoming Zhou, Ira Gupta, Ajay K. Nooka	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact